Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8,708 Mln
Revenue (TTM)
$113 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
-9
Div. Yield
0 %
Debt to Equity
-1.8
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
1,028,111,456
CFO
$-1,483.93 Mln
EBITDA
$-1,875.21 Mln
Net Profit
$-2,291.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immunitybio Inc (IBRX)
| 272.7 | -22.7 | 244.9 | 165.5 | 65.1 | -22.7 | -0.9 |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Immunitybio Inc (IBRX)
| -22.7 | -48.7 | -1.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immunitybio Inc (IBRX)
|
7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 217.0 | 13,621.9 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.... Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California. Read more
Executive Chairman of the Board, Global Chief Scientific & Medical Officer
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Executive Chairman of the Board, Global Chief Scientific & Medical Officer
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Immunitybio Inc (IBRX) is $7.38 (NASDAQ) as of 27-Mar-2026 16:28 EDT. Immunitybio Inc (IBRX) has given a return of 65.1% in the last 3 years.
Since, TTM earnings of Immunitybio Inc (IBRX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.18
|
-3.65
|
|
2024
|
-4.33
|
-3.66
|
|
2023
|
-4.38
|
-4.35
|
|
2022
|
-4.87
|
-4.53
|
|
2021
|
-6.82
|
-9.77
|
The 52-week high and low of Immunitybio Inc (IBRX) are Rs 12.43 and Rs 1.83 as of 28-Mar-2026.
Immunitybio Inc (IBRX) has a market capitalisation of $ 8,708 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Immunitybio Inc (IBRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.